Invivoscribe ® Advances Molecular Clonality Testing Portfolio with Comprehensive LymphoTrack ® Flex Suite
6.10.2026 12:15:00 CEST | Business Wire | Press Release
Invivoscribe, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced the launch of the complete LymphoTrack Flex suite, an integrated next-generation sequencing (NGS) solution to identify and track immunoglobulin and T-cell receptor gene rearrangements.
As NGS-based immune receptor MRD analysis moves from academic laboratories into routine use in oncology research centers, the demand for standardized, high-throughput workflows is accelerating. Laboratories are seeking both greater efficiency and ultra-high sensitivity. This requires increasing DNA inputs while ensuring higher testing throughput and analytical performance. Translational programs need testing that is both reproducible and scalable across sites. LymphoTrack Flex meets these demands, bringing seven molecular targets (IGHV leader, IGH FR1, IGH FR2, IGH FR3, IGK, TRB and TRG), together in one automation-ready workflow with massively parallel multiplexing and a powerful bioinformatics engine to provide objective analyses and tracking of clonal sequences.
“Clonality, somatic hypermutation, and measurable residual disease provide complementary molecular insights across the course of lymphoid malignancies, with growing relevance as treatment approaches evolve beyond fixed-duration therapy toward more dynamic, MRD-informed strategies,” said Brad Patay, Chief Medical Officer of Invivoscribe. “LymphoTrack Flex enables laboratories to characterize clonal populations at baseline and select sequence-specific clonotypes for longitudinal assessments, providing a consistent molecular picture of disease over time to support the evaluation of these evolving treatment approaches.”
The software portfolio provides flexibility across laboratory environments. LymphoTrack Software supports local, desktop-based analysis for labs that want to run testing independently on a single workstation. LymphoTrack Enterprise Software provides a centralized environment for high-throughput analysis, standardized reporting, and integration with laboratory and data infrastructures, enabling labs to scale testing volume without re-architecting laboratory workflow.
“Our vision is to give all laboratories access to optimized MRD assays, controls, and analysis software, with one standardized approach,” said Jeff Miller, CEO of Invivoscribe. “I am incredibly proud of the team behind LymphoTrack Flex. This release is the result of decades of multidisciplinary and international clinical laboratory experience.”
With the complete LymphoTrack Flex suite now available, laboratories can implement a flexible, scalable NGS workflow for clonality assessment, somatic hypermutation analysis, and sequence-based MRD research across a broad range of lymphoid malignancies. Laboratories ready to expand or standardize their NGS clonality and MRD capabilities can learn more at LymphoTrack Flex page or contact inquiry@invivoscribe.com to connect with an Invivoscribe specialist.
About Invivoscribe
Invivoscribe is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics®. For more than thirty years, Invivoscribe has advanced the quality of healthcare worldwide by delivering high-quality, standardized reagents, diagnostic assays, sample preparation systems, and bioinformatics solutions that support precision medicine. The company has a proven track record of partnering with pharmaceutical and biotechnology organizations to support clinical trial testing through its global laboratory network in the United States, Germany, Japan, and China, as well as to develop and commercialize companion diagnostics, leveraging deep expertise in regulatory strategy and laboratory services. By offering both distributable diagnostic kits to over 700 clinical laboratory customers and clinical testing services through its globally located clinical laboratory subsidiaries, LabPMM®, Invivoscribe is an ideal partner across the full diagnostic lifecycle - from development and clinical trials through regulatory submission and commercialization.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261006900484/en/
Contacts
For more information, visit www.invivoscribe.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.invivoscrib
e.com&esheet=54616964&newsitemid=20261006900484&lan=en-US&anchor=www.invivoscrib
e.com&index=2&md5=ebb62702d2076f95950b382f86f976ad, or contact
inquiry@invivoscribe.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Brings Flagship Kinexions Conference to India, Showcasing Growing Market Momentum17.11.2026 02:30:00 CET | Press Release
Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain planning and orchestration, today opened its first-ever Kinexions India conference in Mumbai, highlighting the company's growing presence in the country and India's importance to its global innovation and customer delivery operations. With teams in Chennai and Bangalore supporting product development, engineering, professional services and customer success, India plays an important role in Kinaxis' global operations. The company continues to invest in research and development in India, strengthening its engineering and innovation capabilities to support the next generation of AI and supply chain orchestration technologies. "India plays an important role in how we innovate and support customers around the world," said Razat Gaurav, CEO of Kinaxis. "Bringing Kinexions here for the first time reflects both the strength of India's technology ecosystem and the growing role its enterprises play in shaping global supply chai
Povofortay ® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa16.11.2026 22:30:00 CET | Press Release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Povofortay® (povorcitinib) 45 mg and 75 mg for the treatment of eligible adults with moderate to severe hidradenitis suppurativa (HS). “The European Commission approval of Povofortay marks an important milestone for Incyte, advancing a key growth driver for our business and bringing a new treatment option to people living with HS, a chronic and often debilitating disease,” 2,3 said Bill Meury, Chief Executive Officer, Incyte."As the first and only once-daily oral treatment approved in the European Union for eligible adults with moderate to severe HS, Povofortay gives physicians an important new option for their patients.” The approval is based on results from the pivotal STOP-HS1 (NCT05620823) and STOP-HS2 (NCT05620836) trials evaluating the safety and efficacy of Povofortay in patients with moderate to severe HS.2 Data from the Phase 3 STOP-HS program demonstrated Povofortay’s clinically meaningful and
Lattice Extends Space Heritage with On-Orbit Milestone in TESAT Optical Communication Terminals16.11.2026 22:00:00 CET | Press Release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced that its low power, radiation-resilient Lattice Nexus™ FPGAs have surpassed one year of on-orbit operation in TESAT optical communication terminals. Since launch, the FPGAs have delivered consistent performance in the demanding application of space-based laser communication at 10 Gbps, adding to Lattice’s space heritage of thousands of FPGAs launched to date. TESAT has flown optical communication terminals on GEO and LEO missions for more than a decade, supplying broadband constellations and institutional programs. For the redesign of its terminal electronics, Lattice Nexus FPGAs addressed TESAT’s requirements for radiation tolerance, low power, and board footprint. Built on 28 nm fully depleted silicon-on-insulator (FD-SOI) process technology, the Nexus platform is well suited to a terminal that must run for years without maintenance. “As optical links and onboard processing
Moody’s Names Timothy Bhatt as Chief Information Officer16.11.2026 22:00:00 CET | Press Release
Moody’s Corporation (NYSE: MCO) announced today that it has named Tim Bhatt to the newly created role of Chief Information Officer (CIO), effective December 7th, and that he will join the company’s Executive Leadership Team. Mr. Bhatt, who has served as Chief Technology Officer (CTO) of Moody’s Ratings since 2018, will also continue in that role. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116893391/en/ Timothy Bhatt, Chief Information Officer, Moody's As CIO, Mr. Bhatt will lead Moody’s enterprise technology strategy, AI enablement, and information security, with responsibility for the company’s technology services and operations and cybersecurity teams. He will further modernize how Moody’s operates, bringing together human expertise, trusted data and AI agents to reimagine enterprise workflows and move AI agents from pilots into everyday work. Mr. Bhatt will also continue as Chief Technology Officer of Moody’s Ratin
New Holiday Data From Xsolla Shows Players Are Shopping, Gifting, and Choosing Brands Inside Video Games16.11.2026 18:00:00 CET | Press Release
Xsolla (USA), Inc., a global commerce company, today announced a new data and insights report on how players shop, spend, and respond to brands during the holiday season. Titled “Why Video Games Belong in Your Holiday Commerce Strategy,” the report draws on direct answers from more than 4,000 players, gathered through opt-in rewarded surveys on Xsolla Offerwall. Players chose to take part and received a reward for sharing, which makes the data first-party and consent-based. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111104582/en/ Graphic: Xsolla The research builds on the conversation Xsolla opened at Advertising Week New York 2026 about how brands can reach players in more ways through video games. Combined with Xsolla’s insights into in-game purchasing behavior across an audience of over 300 million players, the survey shows an engaged audience with established spending habits: 84% of respondents call themselves gam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom